Stock · Healthcare
AMGN Amgen Inc. Common Stock
Amgen Inc. Common Stock has a solid dividend profile with no major red flags in the snapshot data.
Why we rate it 7.5
- Yield of 2.62% is in the typical sustainable zone (2-4%)
- Payout ratio of 67% is on the higher side — leaves less buffer for earnings volatility
- Current yield is in line with the 5-year average of 3.07%
- Mega-cap scale (>$200B) — market dominance reduces dividend pressure
Where AMGN ranks
We compute the same 0–10 safety score across 53 dividend-paying stocks and ETFs. Here's where AMGN lands inside that universe.
The universe is curated to the most-searched US dividend payers. We'll expand it as the data layer grows; sector percentiles only appear when we have at least 5 comparable peers.
The two questions a safety score doesn't answer
A safety score tells you how durable AMGN's payout looks. It does not tell you what you keep after tax, or whether something else does the same job better.
On tax: what you actually pocket depends on whether AMGN dividends are qualified — qualified distributions are taxed at 0%, 15%, or 20%, while ordinary ones are taxed at your full marginal rate, a gap that can reach 22 percentage points of the income on the same headline yield.
On substitutes: if AMGN's 7.5/10 score is lower than you want, see AMGN alternatives — same-sector stocks ranked by how closely they match AMGN on both yield and safety, so you can see what a swap actually costs you.
About Amgen Inc. Common Stock
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
How we score dividend safety
The Infnits dividend safety score is a 0–10 rating derived from yield zone, payout ratio (when applicable), yield trend versus 5-year average, instrument type, and company size. Each factor is independently transparent — see the reasons above for exactly which factors contributed to AMGN's score.
For the full methodology including the in-app version that uses ETF look-through and historical cut data, see our methodology page.
This is educational, not investment advice. Dividend safety scores reflect a snapshot of public data on the "as of" date shown. Verify current data on the issuer's investor relations page or your brokerage before making decisions.
Frequently asked questions
Is AMGN safe?
On dividend safety specifically, Infnits scores AMGN 7.5/10 — solid. Amgen Inc. Common Stock has a solid dividend profile with no major red flags in the snapshot data. That score measures how durable the payout looks based on yield zone, payout ratio, yield trend, and instrument type; it does not measure price risk, valuation, or whether AMGN suits your portfolio.
Is AMGN's dividend safe?
Based on snapshot data — yield 2.62%, payout ratio 67%, instrument type stock — Infnits rates AMGN's dividend safety profile as solid (7.5/10). This is one signal, not a recommendation.
What is AMGN's current dividend yield?
AMGN has a current dividend yield of 2.62% as of August 2, 2026. Its 5-year average yield is 3.07%.
How is AMGN's safety score calculated?
The score combines yield zone (yields above 7% historically carry elevated cut risk), payout ratio (lower is safer), trend vs. 5-year average yield, instrument type (ETFs are inherently more diversified), and size (larger companies have more stable cash flows). Each factor is scored 0-2.5 and summed to a 0-10 result.
Where does this data come from?
Fundamentals are sourced from public market data and refreshed regularly. The "as of" date on each page reflects the snapshot used for the score. For real-time data, check the issuer's investor relations page or your brokerage.
Should I buy AMGN based on this score?
No — this is an educational score based on a handful of public signals, not investment advice. Use it as one input among many. For a portfolio-aware analysis with ETF look-through and personalized insights, install the Infnits app.
Get emailed when AMGN score changes.
AMGN head-to-head comparisons
See AMGN compared side-by-side with the most-searched peer tickers — yield, safety, growth trend, expense ratio, and tax treatment.
More AMGN analysis
Other dividend tickers
See how AMGN fits your portfolio
Add your other holdings and the free analyzer shows your total annual income, weighted safety score, and whether AMGN is carrying too much of your income. Runs in your browser — no account, no download.
Or read how safety scoring works.